Metropolitan Life Insurance CO Prelude Therapeutics Inc Transaction History

Metropolitan Life Insurance CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$11.89 - $31.74 $37,976 - $101,377	-3,194 Closed	0 $0
Q3 2021 Jun 21, 2023	BUY	$25.78 - $38.65 $82,341 - $123,448	3,194 New	3,194 $99,000
Q2 2021 Jun 21, 2023	BUY	$28.63 - $44.3 $91,444 - $141,494	3,194 New	3,194 $91,000
Q2 2021 Mar 30, 2023	BUY	$28.63 - $44.3 $9,018 - $13,954	315 Added 10.94%	3,194 $91,000
Q2 2021 Aug 16, 2021	BUY	$28.63 - $44.3 $91,358 - $141,361	3,191 Added 106366.67%	3,194 $91,000
Q1 2021 Jun 26, 2023	BUY	$39.27 - $91.68 $113,058 - $263,946	2,879 New	2,879 $125 Million
Q1 2021 May 14, 2021	SELL	$39.27 - $91.68 $112,940 - $263,671	-2,876 Reduced 99.9%	3 $125,000
Q4 2020 Jun 22, 2023	BUY	$28.81 - $88.94 $82,943 - $256,058	2,879 New	2,879 $205,000
Q4 2020 Mar 30, 2023	BUY	$28.81 - $88.94 $82,943 - $256,058	2,879 New	2,879 $205,000
Q4 2020 Feb 16, 2021	BUY	$28.81 - $88.94 $82,943 - $256,058	2,879 New	2,879 $206,000

35.7M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $34.6M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.